Afmedicinering i danske kliniske behandlingsvejledninger

Carina Lundby; Alaa Hassan Burghle; Jesper Ryg; Larsa Abuna; Walaa Abdulmanem Alnabhan; Jinthusaa Kumaran Thanikaikumaran; Arin Esmael; Jens Søndergaard; A Pottegård

Afmedicinering i danske kliniske behandlingsvejledninger

Carina Lundby^*, Alaa Hassan Burghle, Jesper Ryg, Larsa Abuna, Walaa Abdulmanem Alnabhan, Jinthusaa Kumaran Thanikaikumaran, Arin Esmael, Jens Søndergaard, A Pottegård

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

4 Downloads (Pure)

Abstract

Lack of clinical guidance constitutes a significant barrier to deprescribing. Within Danish clinical guidelines on treatment of dementia, type 2 diabetes, hypertension, and osteoporosis, only limited attention was given to deprescribing. For dementia, type 2 diabetes, and osteoporosis, guidance was primarily focused on when to consider and implement deprescribing, with limited practical guidance on how to deprescribe. No guidance for deprescribing antihypertensives was identified. This highlights a need to consider deprescribing more broadly when developing and updating clinical guidelines, as argued in this review.

Bidragets oversatte titel	Deprescribing in Danish clinical treatment guidelines
Originalsprog	Dansk
Artikelnummer	V01220063
Tidsskrift	Ugeskrift for Læger
Vol/bind	184
Udgave nummer	23
ISSN	0041-5782
Status	Udgivet - dec. 2022

Dokumenter og links

Open Access VersionForlagets udgivne version, 1,29 MBLicens: CC BY-NC-ND

https://ugeskriftet.dk/videnskab/afmedicinering-i-danske-kliniske-behandlingsvejledningerLicens: CC BY-NC-ND

Citationsformater

@article{69b53b869efa4df5af8b135bf5ffd00e,

title = "Afmedicinering i danske kliniske behandlingsvejledninger",

abstract = "Lack of clinical guidance constitutes a significant barrier to deprescribing. Within Danish clinical guidelines on treatment of dementia, type 2 diabetes, hypertension, and osteoporosis, only limited attention was given to deprescribing. For dementia, type 2 diabetes, and osteoporosis, guidance was primarily focused on when to consider and implement deprescribing, with limited practical guidance on how to deprescribe. No guidance for deprescribing antihypertensives was identified. This highlights a need to consider deprescribing more broadly when developing and updating clinical guidelines, as argued in this review.",

author = "Carina Lundby and Burghle, {Alaa Hassan} and Jesper Ryg and Larsa Abuna and Alnabhan, {Walaa Abdulmanem} and Thanikaikumaran, {Jinthusaa Kumaran} and Arin Esmael and Jens S{\o}ndergaard and A Potteg{\aa}rd",

year = "2022",

month = dec,

language = "Dansk",

volume = "184",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "23",

}

TY - JOUR

T1 - Afmedicinering i danske kliniske behandlingsvejledninger

AU - Lundby, Carina

AU - Burghle, Alaa Hassan

AU - Ryg, Jesper

AU - Abuna, Larsa

AU - Alnabhan, Walaa Abdulmanem

AU - Thanikaikumaran, Jinthusaa Kumaran

AU - Esmael, Arin

AU - Søndergaard, Jens

AU - Pottegård, A

PY - 2022/12

Y1 - 2022/12

N2 - Lack of clinical guidance constitutes a significant barrier to deprescribing. Within Danish clinical guidelines on treatment of dementia, type 2 diabetes, hypertension, and osteoporosis, only limited attention was given to deprescribing. For dementia, type 2 diabetes, and osteoporosis, guidance was primarily focused on when to consider and implement deprescribing, with limited practical guidance on how to deprescribe. No guidance for deprescribing antihypertensives was identified. This highlights a need to consider deprescribing more broadly when developing and updating clinical guidelines, as argued in this review.

AB - Lack of clinical guidance constitutes a significant barrier to deprescribing. Within Danish clinical guidelines on treatment of dementia, type 2 diabetes, hypertension, and osteoporosis, only limited attention was given to deprescribing. For dementia, type 2 diabetes, and osteoporosis, guidance was primarily focused on when to consider and implement deprescribing, with limited practical guidance on how to deprescribe. No guidance for deprescribing antihypertensives was identified. This highlights a need to consider deprescribing more broadly when developing and updating clinical guidelines, as argued in this review.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 184

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 23

M1 - V01220063

ER -

Afmedicinering i danske kliniske behandlingsvejledninger

Abstract

Dokumenter og links

Fingeraftryk

Citationsformater